Pharvaris officer exercises options and sells shares

Pharvaris N.V. insider activity centers on an option exercise paired with share sales.

Rhea-AI Filing Summary

Pharvaris N.V. insider activity centers on an option exercise paired with share sales. Principal Accounting Officer Anna Nijdam exercised stock options to acquire 7,330 shares of Common Stock at $20.00 per share, then sold the same number of shares in open-market, cashless transactions on May 21–22, 2026 at weighted average prices around $30.60–$30.74 per share.

Following these transactions, she directly owns 48,945 Common Stock shares. The filing also corrects a prior RSU vesting report, clarifying that total beneficial ownership as of April 11, 2026 should have been 48,945 shares, five more than previously reported due to an overstated tax withholding amount.

Insider Trade Summary

Exercise and Sale: 7,330 shares ($78K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Nijdam Anna

Role Principal Accounting Officer

Sold 7,330 shs ($225K)

Approx. gross sale proceeds $225K

Approx. exercise cost $147K

Approx. pre-tax spread $78K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	5,501	$0.00	$0.00
Exercise	Common Stock	5,501	$20.00	$110K
Sale	Common Stock	5,501	$30.737	$169K
Exercise	Stock Option (Right to Buy)	1,829	$0.00	$0.00
Exercise	Common Stock	1,829	$20.00	$37K
Sale	Common Stock	1,829	$30.6021	$56K

Holdings After Transaction: Stock Option (Right to Buy) — 22,670 contracts (Direct); Common Stock — 48,945 shares (Direct)

Footnotes (4)

1. F1. On April 14, 2026, the reporting person reported an RSU vesting transaction in which 5 additional shares were inadvertently reported as withheld for tax obligations, resulting in an understatement of total beneficial ownership. Following correction of the tax withholding share amount, total beneficial ownership as of April 11, 2026 should have been 48,945 shares rather than 48,940 shares reported previously.
2. F2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.60 to $30.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
3. F3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.60 to $31.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
4. F4. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares sold: 7,330 shares Option exercise price: $20.00 per share Sale price 22 May 2026: $30.7370 per share +4 more

7 metrics

Shares sold 7,330 shares Common Stock sold in open-market transactions on May 21–22, 2026

Option exercise price $20.00 per share Exercise price for Common Stock acquired via stock options

Sale price 22 May 2026 $30.7370 per share Weighted average sale price for 5,501 Common Stock shares

Sale price 21 May 2026 $30.6021 per share Weighted average sale price for 1,829 Common Stock shares

Post-transaction holdings 48,945 shares Common Stock beneficially owned directly after reported transactions

Corrected prior ownership 48,945 shares Beneficial ownership as of April 11, 2026 after RSU tax correction

Options exercised 7,330 shares Total shares acquired through derivative (option) exercises in this filing

Key Terms

cashless exercise transaction, Restricted Stock Unit (RSU) vesting, weighted average sale price, Stock Option (Right to Buy), +1 more

5 terms

cashless exercise transaction financial

"The shares were sold in connection with the exercise of stock options in a cashless exercise transaction."

Restricted Stock Unit (RSU) vesting financial

"the reporting person reported an RSU vesting transaction in which 5 additional shares were inadvertently reported as withheld"

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions"

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

beneficial ownership financial

"resulting in an understatement of total beneficial ownership. Following correction of the tax withholding share amount"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Pharvaris (PHVS) report for Anna Nijdam?

Anna Nijdam exercised stock options and sold the resulting shares. She exercised options for 7,330 Pharvaris Common Stock shares at $20.00 each, then sold all 7,330 shares in open-market, cashless transactions at weighted average prices around $30.60–$30.74 per share.

How many Pharvaris (PHVS) shares did Anna Nijdam sell and at what prices?

She sold 7,330 Pharvaris Common Stock shares. The sales occurred over May 21–22, 2026 at weighted average prices of about $30.60 and $30.74 per share, as part of cashless exercises tied to stock options.

What is Anna Nijdam’s Pharvaris (PHVS) share ownership after these transactions?

After the reported transactions, Anna Nijdam directly owns 48,945 shares. This total reflects her Common Stock holdings following the option exercises and related open-market sales disclosed in the Form 4 filing.

Did the Pharvaris (PHVS) Form 4 include any corrections to prior reports?

Yes, the filing corrects a prior RSU vesting report. It clarifies that, after adjusting an overstated tax withholding of five shares, total beneficial ownership as of April 11, 2026 should have been 48,945 shares instead of 48,940.

What type of stock options did Anna Nijdam exercise at Pharvaris (PHVS)?

She exercised stock options with a $20.00 exercise price. These options, described as a “Stock Option (Right to Buy),” relate to Pharvaris Common Stock and were partially exercised in connection with the reported cashless transactions.

How did Pharvaris (PHVS) describe the sale pricing in Anna Nijdam’s Form 4?

The sales used weighted average prices over multiple trades. Footnotes state that shares were sold in several transactions, with prices ranging from about $30.60 to $31.00, and that detailed trade-level information is available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 05:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijdam Anna

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		M		1,829	A	$20	50,774(1)	D
Common Stock	05/21/2026		S		1,829	D	$30.6021(2)	48,945	D
Common Stock	05/22/2026		M		5,501	A	$20	54,446	D
Common Stock	05/22/2026		S		5,501	D	$30.737(3)	48,945	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	05/21/2026		M			1,829	(4)	02/05/2031	Common Stock	30,000	$0	28,171	D
Stock Option (Right to Buy)	$20	05/22/2026		M			5,501	(4)	02/05/2031	Common Stock	30,000	$0	22,670	D

Explanation of Responses:

1. On April 14, 2026, the reporting person reported an RSU vesting transaction in which 5 additional shares were inadvertently reported as withheld for tax obligations, resulting in an understatement of total beneficial ownership. Following correction of the tax withholding share amount, total beneficial ownership as of April 11, 2026 should have been 48,945 shares rather than 48,940 shares reported previously.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.60 to $30.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.60 to $31.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

4. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Anna Nijdam	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)